Top Markets
#1 Seeker Seeker +121.00%
#2 AI XOVIA AI XOVIA +117.73%
#3 MowCat MowCat +108.08%
#4 Helium Helium +87.29%
#5 Pons Pons +46.79%
#6 UnifAI Network UnifAI Network +34.22%
#7 Zora Zora +31.44%
#8 Bounce Bounce +21.20%
#9 Zylo Ecosystem Zylo Ecosystem +20.84%
#10 Tensor Tensor +20.29%
Coin of the day
Seeker Seeker
Settings
Language
ENGLISH
Currency
USD
Theme
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Rank in Stocks #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Share Price
$1.77
Last synced: 2026-08-28
Market Cap
$660.45M
Change (1 day)
7.26%
Change (1 year)
-9.15%
Country
AU
Trade Clarity Pharmaceuticals Ltd (CU6)

Category

Healthcare
P/E ratio for Clarity Pharmaceuticals Ltd (CU6)
P/E ratio as of 2026 TTM: 0
According to Clarity Pharmaceuticals Ltd latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Clarity Pharmaceuticals Ltd from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
STERIS plc STERIS plc
STERIS plc
STE.US
 28.45 -
IE
Shanghai United Imaging Healthcare Co., Ltd. Shanghai United Imaging Healthcare Co., Ltd.
Shanghai United Imaging Healthcare Co., Ltd.
688271.SS
 - -
CN
Ypsomed Holding AG Ypsomed Holding AG
Ypsomed Holding AG
YPSN.SW
 - -
CH
Medacta Group S.A. Medacta Group S.A.
Medacta Group S.A.
MOVE.SW
 - -
CH
Jafron Biomedical Co.,Ltd. Jafron Biomedical Co.,Ltd.
Jafron Biomedical Co.,Ltd.
300529.SZ
 - -
CN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.